- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02693535
TAPUR: test dell'uso di farmaci approvati dalla Food and Drug Administration (FDA) che mirano a un'anomalia specifica in un gene tumorale nelle persone con cancro in stadio avanzato (TAPUR)
Studio TAPUR (Targeted Agent and Profiling Utilization Registry).
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.
NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers).
********************************************************************
Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress.
********************************************************************
Panoramica dello studio
Stato
Intervento / Trattamento
- Droga: Sunitinib (CLOSED TO ENROLLMENT)
- Droga: Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT)
- Droga: Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT)
- Droga: Olaparib (CLOSED TO ENROLLMENT)
- Droga: Nivolumab and Ipilimumab (CLOSED TO ENROLLMENT)
- Droga: Abemaciclib (CLOSED TO ENROLLMENT)
- Droga: Talazoparib (CLOSED TO ENROLLMENT)
- Droga: Atezolizumab and Talazoparib (CLOSED TO ENROLLMENT)
- Droga: Tucatinib plus Trastuzumab Subcutaneous (SC) (CLOSED TO ENROLLMENT)
- Droga: Futibatinib
- Droga: Dabrafenib plus Trametinib
- Droga: Fam-Trastuzumab Deruxtecan-Nxki (TDxD)
Descrizione dettagliata
The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the safety and efficacy of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic variant. TAPUR will study Food and Drug Administration (FDA)-approved targeted therapies that are contributed by collaborating pharmaceutical companies, catalogue the choice of molecular profiling test by clinical oncologists and develop hypotheses for additional clinical trials.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
Contatti e Sedi
Contatto studio
- Nome: Laurie Smith, MA
- Numero di telefono: www.tapur.org
- Email: tapur@asco.org
Luoghi di studio
-
-
Puerto Rico
-
Cayey, Puerto Rico, Porto Rico, 00737
- Reclutamento
- PanOncology Trials
-
Contatto:
- Natalia Ortiz
- Numero di telefono: 787-407-3333
- Email: natalia.ortiz@panoncologytrials.com
-
Investigatore principale:
- Maria Cruz Correa, MD
-
Dorado, Puerto Rico, Porto Rico, 00646
- Reclutamento
- PanOncology Trials
-
Contatto:
- Natalia Ortiz
- Numero di telefono: 787-407-3333
- Email: natalia.ortiz@panoncologytrials.com
-
Investigatore principale:
- Maria Cruz Correa, MD
-
Manati, Puerto Rico, Porto Rico, 00674
- Reclutamento
- PanOncology Trials
-
Contatto:
- Natalia Ortiz
- Numero di telefono: 787-407-3333
- Email: natalia.ortiz@panoncologytrials.com
-
Investigatore principale:
- Maria Crus Correa, MD
-
Mayagüez, Puerto Rico, Porto Rico, 00680
- Reclutamento
- PanOncology Trials
-
Contatto:
- Natalia Ortiz
- Numero di telefono: 787-407-3333
- Email: natalia.ortiz@panoncologytrials.com
-
Investigatore principale:
- Maria Cruz Correa, MD
-
Ponce, Puerto Rico, Porto Rico, 00730
- Reclutamento
- PanOncology Trials
-
Contatto:
- Natalia Ortiz
- Numero di telefono: 787-407-3333
- Email: natalia.ortiz@panoncologytrials.com
-
Investigatore principale:
- Maria Cruz Correa, MD
-
San Juan, Puerto Rico, Porto Rico, 00909
- Reclutamento
- PanOncology Trials
-
Contatto:
- Natalia Ortiz
- Numero di telefono: 787-407-3333
- Email: natalia.ortiz@panoncologytrials.com
-
Investigatore principale:
- Maria Cruz Correa, MD
-
San Juan, Puerto Rico, Porto Rico, 00935
- Reclutamento
- PanOncology Trials
-
Contatto:
- Natalia Ortiz
- Numero di telefono: 787-407-3333
- Email: natalia.ortiz@panoncologytrials.com
-
Investigatore principale:
- Maria Cruz Correa, MD
-
-
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti, 35294
- Reclutamento
- University of Alabama at Birmingham Comprehensive Cancer Center
-
Investigatore principale:
- Mehmet Akce, MD
-
Contatto:
- Kun Yuan
- Numero di telefono: 205-644-2584
- Email: kunyuan@uabmc.edu
-
-
Arizona
-
Phoenix, Arizona, Stati Uniti, 85338
- Reclutamento
- Cancer Treatment Centers of America-Phoenix
-
Investigatore principale:
- Sagun Shrestha, MD
-
Contatto:
- Alex Lizzul
- Numero di telefono: 602-872-5654
- Email: alizzul@coh.org
-
-
California
-
Auburn, California, Stati Uniti, 95602
- Reclutamento
- Sutter Auburn
-
Contatto:
- Kirsten Babski
- Numero di telefono: 916-878-4990
- Email: BabskiK@sutterhealth.org
-
Investigatore principale:
- Nitin Rohatgi, MD
-
Berkeley, California, Stati Uniti, 94705
- Reclutamento
- Sutter Alta Bates
-
Contatto:
- Christopher Tang
- Numero di telefono: 510-204-3428
- Email: Christopher.Tang@sutterhealth.org
-
Investigatore principale:
- Nitin Rohatgi, MD
-
Los Angeles, California, Stati Uniti, 90025
- Reclutamento
- The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate
-
Contatto:
- Teri Mata
- Numero di telefono: 310-231-2115
- Email: tmata@theangelesclinic.org
-
Investigatore principale:
- Omid Hamid, MD
-
Oakland, California, Stati Uniti, 94611
- Reclutamento
- Kaiser Permanente - Oakland Medical Center
-
Contatto:
- Desiree Goldstein
- Email: desiree.goldstein@kp.org
-
Investigatore principale:
- Jennifer M Suga, MD
-
Palo Alto, California, Stati Uniti, 94301
- Reclutamento
- Sutter Palo Alto Medical Foundation: Palo Alto
-
Contatto:
- Email: clinicaltrials@pamf.org
-
Roseville, California, Stati Uniti, 95661
- Reclutamento
- Kaiser Permanente - Roseville Medical Center
-
Contatto:
- Desiree Goldstein
- Email: desiree.goldstein@kp.org
-
Investigatore principale:
- Jennifer M Suga, MD
-
Roseville, California, Stati Uniti, 95661
- Reclutamento
- Sutter Roseville
-
Contatto:
- Kirsten Babski
- Numero di telefono: 916-878-4990
- Email: BabskiK@sutterhealth.org
-
Investigatore principale:
- Nitin Rohatgi, MD
-
Sacramento, California, Stati Uniti, 95814
- Reclutamento
- Kaiser Permanente - Sacramento Medical Center
-
Contatto:
- Desiree Goldstein
- Email: desiree.goldstein@kp.org
-
Investigatore principale:
- Jennifer M Suga, MD
-
Sacramento, California, Stati Uniti, 95816
- Reclutamento
- Sutter Sacramento
-
Contatto:
- Email: SIMR@sutterhealth.org
-
Investigatore principale:
- Nitin Rohatgi, MD
-
San Francisco, California, Stati Uniti, 94115
- Reclutamento
- California Pacific Medical Center Research Institute
-
Contatto:
- Numero di telefono: 415-600-1654
- Email: clinicalresearch@sutterhealth.org
-
Investigatore principale:
- Nitin Rohatgi, MD
-
San Francisco, California, Stati Uniti, 94080
- Reclutamento
- Kaiser Permanente - South San Francisco Medical Center
-
Contatto:
- Desiree Goldstein
- Email: desiree.goldstein@kp.org
-
Investigatore principale:
- Jennifer M Suga, MD
-
San Francisco, California, Stati Uniti, 94115
- Reclutamento
- Kaiser Permanente - San Francisco Medical Center
-
Contatto:
- Desiree Goldstein
- Email: desiree.goldstein@kp.org
-
Investigatore principale:
- Jennifer M Suga, MD
-
San Francisco, California, Stati Uniti, 94115
- Reclutamento
- Sutter Cancer Research Consortium
-
Contatto:
- Laurel Brechtel
- Numero di telefono: 415-600-1654
- Email: BrechtLa@cpmcri.org
-
Investigatore principale:
- Stacy D'Andre, MD
-
San Jose, California, Stati Uniti, 95119
- Reclutamento
- Kaiser Permanente - San Jose Medical Center
-
Contatto:
- Desiree Goldstein
- Email: desiree.goldstein@kp.org
-
Investigatore principale:
- Jennifer M Suga, MD
-
San Leandro, California, Stati Uniti, 94577
- Reclutamento
- Kaiser Permanente - San Leandro Medical Center
-
Contatto:
- Desiree Goldstein
- Email: desiree.goldstein@kp.org
-
Investigatore principale:
- Jennifer M Suga, MD
-
Santa Barbara, California, Stati Uniti, 93105
- Reclutamento
- Sutter Sansum Clinic
-
Investigatore principale:
- Nitin Rohatgi, MD
-
Contatto:
- Selina Perez
- Numero di telefono: 831-458-5837
- Email: Selina.Perez@sutterhealth.org
-
Santa Clara, California, Stati Uniti, 95051
- Reclutamento
- Kaiser Permanente - Santa Clara Medical Center
-
Contatto:
- Desiree Goldstein
- Email: desiree.goldstein@kp.org
-
Investigatore principale:
- Jennifer M Suga, MD
-
Santa Cruz, California, Stati Uniti, 95065
- Reclutamento
- Sutter Palo Alto Medical Foundation: Santa Cruz
-
Contatto:
- Email: clinicaltrials@pamf.org
-
Santa Cruz, California, Stati Uniti, 994538
- Reclutamento
- Sutter Palo Alto Medical Foundation: Fremont
-
Contatto:
- Email: clinicaltrials@pamf.org
-
Sunnyvale, California, Stati Uniti, 94086
- Reclutamento
- Sutter Palo Alto Medical Foundation: Sunnyvale
-
Contatto:
- Email: clinicaltrials@pamf.org
-
Vallejo, California, Stati Uniti, 94589
- Reclutamento
- Kaiser Permanente - Vallejo Medical Center
-
Contatto:
- Desiree Goldstein
- Email: desiree.goldstein@kp.org
-
Investigatore principale:
- Jennifer M. Suga, MD
-
Walnut Creek, California, Stati Uniti, 94596
- Reclutamento
- Kaiser Permanente - Walnut Creek Medical Center
-
Contatto:
- Desiree Goldstein
- Email: desiree.goldstein@kp.org
-
Investigatore principale:
- Jennifer M Suga, MD
-
-
Connecticut
-
Bridgeport, Connecticut, Stati Uniti, 06606
- Reclutamento
- Saint Vincent's Medical Center (SVMC)
-
Contatto:
- Numero di telefono: 860-972-4700
- Email: CancerResearchSupport@hhchealth.org
-
Investigatore principale:
- Wylie Hosmer, MD
-
Hartford, Connecticut, Stati Uniti, 06102
- Reclutamento
- Hartford Hospital
-
Contatto:
- Numero di telefono: 860-972-4700
- Email: CancerResearchSupport@hhchealth.org
-
Investigatore principale:
- Wylie Hosmer, MD
-
Meriden, Connecticut, Stati Uniti, 06451
- Reclutamento
- Midstate Medical Center (MSMC)
-
Contatto:
- Numero di telefono: 860-972-4700
- Email: CancerResearchSupport@hhchealth.org
-
Investigatore principale:
- Wylie Hosmer, MD
-
New Britain, Connecticut, Stati Uniti, 06053
- Reclutamento
- The Hospital of Central Connecticut (HOCC) Cancer Center
-
Investigatore principale:
- Wylie Hosmer, MD
-
Contatto:
- Numero di telefono: 8609724700
- Email: CancerResearchSupport@hhchealth.org
-
Norwich, Connecticut, Stati Uniti, 06360
- Reclutamento
- William W. Backus Hospital
-
Contatto:
- Numero di telefono: 860-972-4700
- Email: CancerResearchSupport@hhchealth.org
-
Investigatore principale:
- Wylie Hosmer, MD
-
Torrington, Connecticut, Stati Uniti, 06790
- Reclutamento
- Charlotte Hungerford
-
Contatto:
- Numero di telefono: 860-972-4700
- Email: CancerResearchSupport@hhchealth.org
-
Investigatore principale:
- Wylie Hosmer, MD
-
Willimantic, Connecticut, Stati Uniti, 06226
- Reclutamento
- Windham Hospital (WH)
-
Contatto:
- Numero di telefono: 860-972-4700
- Email: CancerResearchSupport@hhchealth.org
-
Investigatore principale:
- Wylie Hosmer, MD
-
-
Florida
-
Altamonte Springs, Florida, Stati Uniti, 32701
- Attivo, non reclutante
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Aventura, Florida, Stati Uniti, 33180
- Reclutamento
- University of Miami/Sylvester Cancer Institute - Aventura
-
Contatto:
- Carolina Troche, BS
- Numero di telefono: 305-243-1481
- Email: cxt582@med.miami.edu
-
Investigatore principale:
- Carmen Calfa, MD
-
Bonita Springs, Florida, Stati Uniti, 34135
- Attivo, non reclutante
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Bradenton, Florida, Stati Uniti, 34211
- Attivo, non reclutante
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Brandon, Florida, Stati Uniti, 33511
- Attivo, non reclutante
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Cape Coral, Florida, Stati Uniti, 33909
- Attivo, non reclutante
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Clearwater, Florida, Stati Uniti, 33761
- Attivo, non reclutante
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Coral Gables, Florida, Stati Uniti, 33146
- Reclutamento
- University of Miami/Sylvester Cancer Institute - Lennar
-
Contatto:
- Carolina Troche, BS
- Numero di telefono: 305-243-1481
- Email: cxt582@med.miami.edu
-
Investigatore principale:
- Carmen Calfa, MD
-
Deerfield Beach, Florida, Stati Uniti, 33442
- Reclutamento
- University of Miami/Sylvester Cancer Institute - Deerfield Beach
-
Contatto:
- Carolina Troche, BS
- Numero di telefono: 305-243-1481
- Email: cxt582@med.miami.edu
-
Investigatore principale:
- Carmen Calfa, MD
-
Fort Lauderdale, Florida, Stati Uniti, 33308
- Reclutamento
- Holy Cross Hospital
-
Investigatore principale:
- Zdenka Segota, MD
-
Contatto:
- Numero di telefono: 7347123671
- Email: MCRCwebsitecontactform@trinity-health.org
-
Fort Myers, Florida, Stati Uniti, 33901
- Attivo, non reclutante
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Fort Myers, Florida, Stati Uniti, 33905
- Attivo, non reclutante
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Fort Myers, Florida, Stati Uniti, 33908
- Attivo, non reclutante
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Gainesville, Florida, Stati Uniti, 32610
- Reclutamento
- University of Florida Health
-
Investigatore principale:
- Thomas George, MD
-
Contatto:
- Anna Kukulka, RN, BSN
- Numero di telefono: 352-293-2551
- Email: akukulka@ufl.edu
-
Gainesville, Florida, Stati Uniti, 32605
- Attivo, non reclutante
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Largo, Florida, Stati Uniti, 33770
- Attivo, non reclutante
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Lecanto, Florida, Stati Uniti, 34461
- Attivo, non reclutante
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Miami, Florida, Stati Uniti, 33136
- Reclutamento
- University of Miami Sylvester Comprehensive Cancer Center
-
Contatto:
- Carolina Troche, BS
- Numero di telefono: 305-243-1481
- Email: cxt582@med.miami.edu
-
Investigatore principale:
- Carmen Calfa, MD
-
Miami, Florida, Stati Uniti, 33136
- Reclutamento
- University of Miami/Sylvester Cancer Institute - Alex's Place
-
Contatto:
- Carolina Troche, BS
- Numero di telefono: 305-243-1481
- Email: cxt582@med.miami.edu
-
Investigatore principale:
- Carmen Calfa, MD
-
Miami, Florida, Stati Uniti, 33136
- Reclutamento
- University of Miami/Sylvester Cancer Institute - Griffin Cancer Research Building
-
Contatto:
- Carolina Troche, BS
- Numero di telefono: 305-243-1481
- Email: cxt582@med.miami.edu
-
Investigatore principale:
- Carmen Calfa, MD
-
Miami, Florida, Stati Uniti, 33176
- Reclutamento
- University of Miami/Sylvester Cancer Institute - Kendall
-
Contatto:
- Carolina Troche, BS
- Numero di telefono: 305-243-1481
- Email: cxt582@med.miami.edu
-
Investigatore principale:
- Carmen Calfa, MD
-
Miami, Florida, Stati Uniti, 33181
- Reclutamento
- University of Miami/Sylvester Cancer Institute - Sole Mia
-
Contatto:
- Carolina Troche, BS
- Numero di telefono: 305-243-1481
- Email: cxt582@med.miami.edu
-
Investigatore principale:
- Carmen Calfa, MD
-
Naples, Florida, Stati Uniti, 34102
- Attivo, non reclutante
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Ocala, Florida, Stati Uniti, 34474
- Attivo, non reclutante
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Orange City, Florida, Stati Uniti, 32763
- Attivo, non reclutante
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Orlando, Florida, Stati Uniti, 32806
- Attivo, non reclutante
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Plantation, Florida, Stati Uniti, 33324
- Reclutamento
- University of Miami/Sylvester Cancer Institute - Plantation
-
Contatto:
- Carolina Troche, BS
- Numero di telefono: 305-243-1481
- Email: cxt582@med.miami.edu
-
Investigatore principale:
- Carmen Calfa, MD
-
Port Charlotte, Florida, Stati Uniti, 33980
- Attivo, non reclutante
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Sarasota, Florida, Stati Uniti, 34236
- Attivo, non reclutante
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Sarasota, Florida, Stati Uniti, 34239
- Attivo, non reclutante
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
St. Petersburg, Florida, Stati Uniti, 33701
- Attivo, non reclutante
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Tampa, Florida, Stati Uniti, 33607
- Attivo, non reclutante
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Tavares, Florida, Stati Uniti, 32778
- Attivo, non reclutante
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
The Villages, Florida, Stati Uniti, 32159
- Attivo, non reclutante
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Trinity, Florida, Stati Uniti, 34655
- Attivo, non reclutante
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Venice, Florida, Stati Uniti, 34285
- Attivo, non reclutante
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Venice, Florida, Stati Uniti, 34292
- Attivo, non reclutante
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Winter Park, Florida, Stati Uniti, 32789
- Attivo, non reclutante
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30322
- Reclutamento
- Emory University Winship Cancer Institute
-
Investigatore principale:
- Olatunji Alese, MD
-
Contatto:
- Krystal Bagley
- Numero di telefono: 404-778-8670
- Email: krystal.joi.bagley@emory.edu
-
Atlanta, Georgia, Stati Uniti, 30265
- Reclutamento
- Cancer Treatment Centers of America - Atlanta
-
Investigatore principale:
- Bamidele Adesunloye, MD
-
Contatto:
- Elizabeth McKoy, RN, BSN
- Numero di telefono: 770-400-7177
- Email: emckoy@coh.org
-
Savannah, Georgia, Stati Uniti, 31405
- Reclutamento
- Summit Cancer Care
-
Investigatore principale:
- Mark Taylor, MD
-
Contatto:
- Stephanie Smith, RN, MSN, OCN
- Numero di telefono: 9128195723
- Email: smiths1@sjchs.org
-
Savannah, Georgia, Stati Uniti, 31405
- Reclutamento
- Gynecologic Oncology and Surgical Specialists at the Lewis Cancer & Research Pavilion
-
Investigatore principale:
- Mark Taylor, MD
-
Contatto:
- Stephanie Smith, RN, MSN, OCN
- Numero di telefono: 9128195723
- Email: smiths1@sjchs.org
-
Savannah, Georgia, Stati Uniti, 31405
- Reclutamento
- Lewis Cancer & Research Pavilion at the Melanoma, Skin Cancer & Sarcoma Institute
-
Investigatore principale:
- Mark Taylor, MD
-
Contatto:
- Stephanie Smith, RN, MSN, OCN
- Numero di telefono: 19128195723
- Email: smiths1@sjchs.org
-
Savannah, Georgia, Stati Uniti, 31405
- Reclutamento
- Lewis Cancer & Research Pavilion
-
Contatto:
- Stephanie Smith, RN, MSN, OCN
- Numero di telefono: 912-819-5723
- Email: smiths1@sjchs.org
-
Investigatore principale:
- Mark Taylor, MD
-
-
Hawaii
-
Honolulu, Hawaii, Stati Uniti, 96813
- Reclutamento
- The Queen's Medical Center - POB I
-
Investigatore principale:
- Jared Acoba, MD
-
Contatto:
- Tim Kelleher
- Numero di telefono: 8086918582
- Email: tkelleher@queens.org
-
Honolulu, Hawaii, Stati Uniti, 96813
- Reclutamento
- The Queen's Medical Center - Punchbowl
-
Investigatore principale:
- Jared Acoba, MD
-
Contatto:
- Tim Kelleher
- Numero di telefono: 808 691-8582
- Email: tkelleher@queens.org
-
Honolulu, Hawaii, Stati Uniti, 96817
- Reclutamento
- The Queen's Medical Center - Kuakini
-
Investigatore principale:
- Jared Acoba, MD
-
Contatto:
- Tim Kelleher
- Numero di telefono: 8086918582
- Email: tkelleher@queens.org
-
‘Ewa Beach, Hawaii, Stati Uniti, 96706
- Reclutamento
- The Queen's Medical Center - West Oahu
-
Investigatore principale:
- Jared Acoba, MD
-
Contatto:
- Tim Kelleher
- Numero di telefono: 8086918582
- Email: tkelleher@queens.org
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60099
- Reclutamento
- Cancer Treatment Centers of America-Chicago
-
Investigatore principale:
- Evan Pisick, MD
-
Contatto:
- Office of Clinical Trials
- Numero di telefono: 847-731-1777
- Email: CHIResearch@coh.org
-
-
Indiana
-
Indianapolis, Indiana, Stati Uniti, 46250
- Reclutamento
- Community Health Network (The University of Texas MD Anderson Cancer Center)
-
Investigatore principale:
- Funda Meric-Bernstam, MD
-
Contatto:
- Kshipra Sharma, MPH, MS
- Numero di telefono: 713-745-8431
- Email: Ksharma2@MDAnderson.org
-
-
Maine
-
Augusta, Maine, Stati Uniti, 04330
- Reclutamento
- Harold Alfond Center for Cancer Care
-
Contatto:
- Sandra Neptune, BSN, RN
- Numero di telefono: 207-626-4811
- Email: sandra.neptune@mainegeneral.org
-
Investigatore principale:
- Lindsay Hathaway, MD
-
Augusta, Maine, Stati Uniti, 04330
- Reclutamento
- Jackson Laboratory - Maine Cancer Genomics Initiative
-
Contatto:
- Petra Helbig, CCRP
- Numero di telefono: 207-664-4659
- Email: Petra.Helbig@jax.org
-
Investigatore principale:
- Jens Rueter, MD
-
Belfast, Maine, Stati Uniti, 04915
- Reclutamento
- Waldo County General Hospital
-
Investigatore principale:
- Roger Inhorn, MD
-
Contatto:
- Jen - Dalton, MHA, BSN, RN
- Numero di telefono: 2072948291
- Email: JDalton@mmc.org
-
Biddeford, Maine, Stati Uniti, 04005
- Reclutamento
- SMHC Cancer Care and Blood Disorders -Biddeford
-
Investigatore principale:
- Roger Inhorn, MD
-
Contatto:
- Jen - Dalton
- Numero di telefono: 2072948291
- Email: JDalton@mmc.org
-
Brewer, Maine, Stati Uniti, 04412
- Reclutamento
- Northern Light Cancer Care
-
Investigatore principale:
- Sarah Sinclair, MD
-
Contatto:
- Carla Mancini, MHA, BSN, RN
- Numero di telefono: 207-973-5581
- Email: cmancini@northernlight.org
-
Brewer, Maine, Stati Uniti, 04412
- Reclutamento
- Raish Peavey Haskell Children's Cancer and Treatment Center
-
Investigatore principale:
- Sarah Sinclair, MD
-
Contatto:
- Carla C Mancini, RN, BSN, OCN
- Numero di telefono: 2079735581
- Email: cmancini@northernlight.org
-
Brunswick, Maine, Stati Uniti, 04011
- Reclutamento
- MaineHealth Cancer Care -Brunswick
-
Investigatore principale:
- Roger Inhorn, MD
-
Contatto:
- Jen - Dalton, MHA, BSN, RN
- Numero di telefono: 2072948291
- Email: JDalton@mmc.org
-
Kennebunk, Maine, Stati Uniti, 04043
- Reclutamento
- New England Cancer Specialist
-
Investigatore principale:
- Christian Thomas, MD
-
Contatto:
- Patricia C Collins
- Numero di telefono: 2073033422
- Email: collip@newecs.org
-
Kittery, Maine, Stati Uniti, 03904
- Reclutamento
- York Hopsital Oncology & Infusion Care in Kittery
-
Investigatore principale:
- Marilyn McLaughlin, MD
-
Contatto:
- Brenda i Kiberd, RN
- Numero di telefono: 2073616115
- Email: Brenda.Kiberd@yorkhospital.com
-
Norway, Maine, Stati Uniti, 04268
- Reclutamento
- Stephens Memorial Hospital
-
Investigatore principale:
- Roger Inhorn, MD
-
Contatto:
- Jen - Dalton, MHA, BSN, RN
- Numero di telefono: 2072948291
- Email: JDalton@mmc.org
-
Rockport, Maine, Stati Uniti, 04856
- Reclutamento
- Penobscot Bay Medical Center
-
Investigatore principale:
- Roger Inhorn, MD
-
Contatto:
- Jen - Dalton, MHA, BSN, RN
- Numero di telefono: 2072948291
- Email: JDalton@mmc.org
-
Sanford, Maine, Stati Uniti, 04073
- Reclutamento
- SMHC Cancer Care and Blood Disorders -Sandford
-
Investigatore principale:
- Roger Inhorn, MD
-
Contatto:
- Jen - Dalton, MHA, BSN, RN
- Numero di telefono: 2072948291
- Email: JDalton@mmc.org
-
Scarborough, Maine, Stati Uniti, 04074
- Reclutamento
- Maine Children's Cancer Program
-
Investigatore principale:
- Roger Inhorn, MD
-
Contatto:
- Jen - Dalton, MHA, BSN, RN
- Numero di telefono: 2072948291
- Email: JDalton@mmc.org
-
Scarborough, Maine, Stati Uniti, 04074
- Reclutamento
- Maine Medical Partner's Women's Health
-
Investigatore principale:
- Roger Inhorn, MD
-
Contatto:
- Jen - Dalton, MHA, BSN, RN
- Numero di telefono: 2072948291
- Email: JDalton@mmc.org
-
Scarborough, Maine, Stati Uniti, 04074
- Reclutamento
- New England Cancer Specialist
-
Investigatore principale:
- Christian Thomas, MD
-
Contatto:
- Patricia Collins, BA, CCRC
- Numero di telefono: 207-303-3422
- Email: collip@newecs.org
-
South Portland, Maine, Stati Uniti, 04106
- Reclutamento
- MaineHealth Cancer Care -South Portland
-
Contatto:
- Jen Dalton, MHA, BSN, RN
- Numero di telefono: 207-294-8291
- Email: JDalton@mmc.org
-
Investigatore principale:
- Roger Inhorn, MD
-
Topsham, Maine, Stati Uniti, 04086
- Reclutamento
- New England Cancer Specialist
-
Investigatore principale:
- Christian Thomas, MD
-
Contatto:
- Patricia C Collins, BA, CCRC
- Numero di telefono: 12073033422
- Email: collip@newecs.org
-
Wells, Maine, Stati Uniti, 04090
- Reclutamento
- York Hospital Oncology & Infusion Care in Wells
-
Investigatore principale:
- Marilyn McLaughlin, MD
-
Contatto:
- Brenda Kiberd, RN
- Numero di telefono: 207-361-6115
- Email: Brenda.Kiberd@yorkhospital.com
-
York Village, Maine, Stati Uniti, 03909
- Reclutamento
- York Hospital Oncology & Infusion Care in York
-
Investigatore principale:
- Marilyn McLaughlin, MD
-
Contatto:
- Brenda i Kiberd, RN
- Numero di telefono: 2073616115
- Email: Brenda.Kiberd@yorkhospital.com
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48109
- Attivo, non reclutante
- University of Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48106
- Reclutamento
- Trinity Health Ann Arbor Hospital
-
Investigatore principale:
- Elie Dib, MD
-
Contatto:
- Numero di telefono: 7347123671
- Email: MCRCwebsitecontactform@trinity-health.org
-
Detroit, Michigan, Stati Uniti, 48236
- Reclutamento
- Henry Ford Health Saint John Hospital
-
Investigatore principale:
- Carrie Dul, MD
-
Contatto:
- Numero di telefono: 7347123671
- Email: MCRCwebsitecontactform@trinity-health.org
-
Flint, Michigan, Stati Uniti, 48503
- Reclutamento
- Genesys Hurley Cancer Institute
-
Investigatore principale:
- Paul Adams, MD
-
Contatto:
- Numero di telefono: 7347123671
- Email: MCRCwebsitecontactform@trinity-health.org
-
Grand Rapids, Michigan, Stati Uniti, 49503
- Reclutamento
- Cancer Research Consortium of West Michigan
-
Contatto:
- Connie Szczepanek, RN
- Numero di telefono: 616-391-1230
- Email: crcwm-regulatory@crcwm.org
-
Investigatore principale:
- Kathleen J. Yost, MD
-
Lansing, Michigan, Stati Uniti, 48912
- Reclutamento
- University of Michigan Health - Sparrow Lansing
-
Investigatore principale:
- Gordan Srkalovic, MD
-
Contatto:
- Numero di telefono: 7347123671
- Email: MCRCwebsitecontactform@trinity-health.org
-
Livonia, Michigan, Stati Uniti, 48154
- Reclutamento
- Trinity Health Livonia Hospital
-
Investigatore principale:
- Amit Mohindra, MD
-
Contatto:
- Numero di telefono: 7347127251
- Email: MCRCwebsitecontactform@trinity-health.org
-
Pontiac, Michigan, Stati Uniti, 48341
- Reclutamento
- Trinity Health Oakland Hospital
-
Investigatore principale:
- Julie Goodman, MD
-
Contatto:
- Numero di telefono: 7347123671
- Email: MCRCwebsitecontactform@trinity-health.org
-
Saginaw, Michigan, Stati Uniti, 48601
- Reclutamento
- MyMichigan Medical Center Saginaw
-
Investigatore principale:
- Nicholas Damico, MD
-
Contatto:
- Numero di telefono: 7347123671
- Email: MCRCwebsitecontactform@trinity-health.org
-
Traverse City, Michigan, Stati Uniti, 48341
- Reclutamento
- Michigan Cancer Research Consortium
-
Investigatore principale:
- Philip Stella, MD
-
Contatto:
- Beth LaVasseur, RN, MS
- Numero di telefono: 734-712-7251
- Email: Beth.LaVasseur@stjoeshealth.org
-
Contatto:
- Numero di telefono: 877-590-5995
-
Warren, Michigan, Stati Uniti, 48093
- Reclutamento
- Henry Ford Health Warren Hospital
-
Investigatore principale:
- Carrie Dul, MD
-
Contatto:
- Numero di telefono: 7347123671
- Email: MCRCwebsitecontactform@trinity-health.org
-
-
Nebraska
-
Omaha, Nebraska, Stati Uniti, 68198
- Reclutamento
- University of Nebraska Medical Center
-
Investigatore principale:
- Alissa Marr, MD
-
Contatto:
- Micki Bethea, BS
- Numero di telefono: 402-559-8011
- Email: mbethea@unmc.edu
-
-
New Hampshire
-
Concord, New Hampshire, Stati Uniti, 03103
- Reclutamento
- NH Oncology - Hematology, PA
-
Contatto:
- Ali Fleury
- Numero di telefono: 6033146888
- Email: A.Fleury@nhoh.com
-
Investigatore principale:
- Michael Buff, MD
-
Manchester, New Hampshire, Stati Uniti, 03103
- Reclutamento
- Solinsky Center for Cancer Care
-
Contatto:
- Ali Fleury, BA, CCRP
- Numero di telefono: 603-314-6888
- Email: A.Fleury@nhoh.com
-
Investigatore principale:
- Michael Buff, MD
-
Portsmouth, New Hampshire, Stati Uniti, 03801
- Reclutamento
- New England Cancer Specialist
-
Investigatore principale:
- Christian Thomas, MD
-
Contatto:
- Patricia C Collins, BA, CCRC
- Numero di telefono: 2073033422
- Email: collip@newecs.org
-
-
New Mexico
-
Albuquerque, New Mexico, Stati Uniti, 87110
- Reclutamento
- Presbyterian Kaseman Hospital
-
Investigatore principale:
- Bernard Tawfik, MD
-
Contatto:
- Monique Robertson, RN
- Numero di telefono: (505)- 559-6100
- Email: mrobertso2@phs.org
-
Albuquerque, New Mexico, Stati Uniti, 87102
- Reclutamento
- Lovelace Medical Center - Saint Joseph Square
-
Investigatore principale:
- Bernard Tawfik, MD
-
Contatto:
- Leslie Byatt
- Numero di telefono: (505) -925-0366
- Email: lpbyatt@salud.unm.edu
-
Albuquerque, New Mexico, Stati Uniti, 87131
- Reclutamento
- The University of New Mexico Comprehensive Cancer Center
-
Investigatore principale:
- Bernard Tawfik, MD
-
Contatto:
- Sheri Westgate, RN-BSN, OCN
- Numero di telefono: (505) -925-0383
- Email: swestgate@salud.unm.edu
-
Las Cruces, New Mexico, Stati Uniti, 88011
- Reclutamento
- Memorial Medical Center
-
Investigatore principale:
- Bernard Tawfik, MD
-
Contatto:
- Kim Hoffman, RN
- Numero di telefono: (575)- 556-6545
- Email: kim.hoffman@lpnt.net
-
Rio Rancho, New Mexico, Stati Uniti, 87124
- Reclutamento
- Presbyterian Rust Medical Center
-
Investigatore principale:
- Bernard Tawfik, MD
-
Contatto:
- Andrea Yost
- Numero di telefono: (505) -253-7878
- Email: ayost3@phs.org
-
-
New York
-
Lake Success, New York, Stati Uniti, 11042
- Reclutamento
- Northwell Health Monter Cancer Center
-
Contatto:
- Mary Agnes Templeton
- Numero di telefono: 516-734-8979
- Email: mtempleton@northwell.edu
-
Investigatore principale:
- Marina Frimer, MD
-
Mount Kisco, New York, Stati Uniti, 10549
- Reclutamento
- Northern Westchester Hospital
-
Investigatore principale:
- Marina Frimer, MD
-
Contatto:
- Jemima Jacob, MPH
- Numero di telefono: 914-666-1366
- Email: jjacob22@northwell.edu
-
New Hyde Park, New York, Stati Uniti, 11040
- Reclutamento
- Cohen Children's Medical Center
-
Contatto:
- Shreya Seepersaud
- Numero di telefono: 718-470-7146
- Email: sseepersaud2@northwell.edu
-
Investigatore principale:
- Marina Frimer, MD
-
New York, New York, Stati Uniti, 10065
- Reclutamento
- Manhattan Eye, Ear, and Throat Hospital
-
Investigatore principale:
- Marina Frimer, MD
-
Contatto:
- Leila Nasr
- Email: lnasr@northwell.edu
-
New York, New York, Stati Uniti, 10305
- Reclutamento
- Staten Island University Hospital
-
Investigatore principale:
- Marina Frimer, MD
-
Contatto:
- Sammi Ruan
- Numero di telefono: 718-226-1489
- Email: sruan2@northwell.edu
-
Contatto:
- Melissa McCarthy
- Numero di telefono: 718-226-1805
- Email: mccarthy22@northwell.edu
-
Rego Park, New York, Stati Uniti, 11374
- Reclutamento
- Queens Cancer Center
-
Investigatore principale:
- Marina Frimer, MD
-
Contatto:
- Harmandeep Kaur
- Numero di telefono: 718-412-0773
- Email: hkaur37@northwell.edu
-
Sleepy Hollow, New York, Stati Uniti, 10591
- Reclutamento
- Phelps Hospital
-
Investigatore principale:
- Marina Frimer, MD
-
Contatto:
- Barbara Turner, RN
- Numero di telefono: 914-269-1949
- Email: Bturner1@northwell.edu
-
Contatto:
- Shyrley Gomez
- Email: Sgomez21@northwell.edu
-
-
North Carolina
-
Chapel Hill, North Carolina, Stati Uniti, 27599
- Reclutamento
- Lineberger Comprehensive Cancer Center
-
Investigatore principale:
- Shetal Patel, MD
-
Contatto:
- Emmie Cole
- Numero di telefono: 919-966-4432
- Email: emmie_cole@med.unc.edu
-
Charlotte, North Carolina, Stati Uniti, 28277
- Reclutamento
- Atrium Health's Levine Cancer Institute
-
Investigatore principale:
- Kathryn F. Mileham, MD, FACP
-
Contatto:
- Jenna Gregory, MS, RN
- Email: Jenna.Gregory@atriumhealth.org
-
-
North Dakota
-
Bismarck, North Dakota, Stati Uniti, 58501
- Reclutamento
- Sanford Health- Bismarck
-
Contatto:
- Peter Kurniali, MD
- Numero di telefono: 701-323-5741
- Email: peter.kurniali@sanfordhealth.org
-
Investigatore principale:
- Peter Kurniali, MD
-
Fargo, North Dakota, Stati Uniti, 58122
- Reclutamento
- Sanford Health- Fargo
-
Contatto:
- Anu Gaba, MD
- Numero di telefono: 701-234-6161
- Email: anu.gaba@sanfordhealth.org
-
Investigatore principale:
- Anu Gaba, MD
-
-
Ohio
-
Cincinnati, Ohio, Stati Uniti, 45219
- Reclutamento
- University of Cincinnati Medical Center
-
Investigatore principale:
- Davendra Sohal, MD
-
Contatto:
- Kayla Webb, MSN, RN
- Numero di telefono: 513-584-0599
- Email: webb2ka@ucmail.uc.edu
-
Kettering, Ohio, Stati Uniti, 45429
- Reclutamento
- Kettering Health
-
Contatto:
- Allison Dymacek, BSN, RN
- Numero di telefono: 937-395-8367
- Email: allison.dymacek@ketteringhealth.org
-
Investigatore principale:
- Lex Leonhardt, DO
-
West Chester, Ohio, Stati Uniti, 45069
- Reclutamento
- West Chester Hospital
-
Investigatore principale:
- Trisha Wise-Draper, MD
-
Contatto:
- Kayla Webb, MSN, RN
- Numero di telefono: 513-584-0599
- Email: webb2ka@ucmail.uc.edu
-
-
Oregon
-
Portland, Oregon, Stati Uniti, 97213
- Reclutamento
- Providence Health & Services
-
Investigatore principale:
- Evthokia Hobbs, MD
-
Contatto:
- Isa Ngirailemesang
- Numero di telefono: 971-358-2056
- Email: Isa.Ngirailemesang@providence.org
-
-
Pennsylvania
-
Allentown, Pennsylvania, Stati Uniti, 18103
- Reclutamento
- Lehigh Valley Hospital - Cedar Crest
-
Contatto:
- Numero di telefono: 734-712-3671
- Email: MCRCwebsitecontactform@trinity-health.org
-
Investigatore principale:
- Maged Khalil, MD
-
Bethlehem, Pennsylvania, Stati Uniti, 18017
- Reclutamento
- Lehigh Valley Hospital- Muhlenberg
-
Investigatore principale:
- Maged Khalil, MD
-
Contatto:
- Numero di telefono: 7347127251
- Email: MCRCwebsitecontactform@trinity-health.org
-
East Stroudsburg, Pennsylvania, Stati Uniti, 18301
- Reclutamento
- Pocono Medical Center
-
Investigatore principale:
- Maged Khalil, MD
-
Contatto:
- Numero di telefono: 7347127251
- Email: MCRCwebsitecontactform@trinity-health.org
-
Hazleton, Pennsylvania, Stati Uniti, 18201
- Reclutamento
- Lehigh Valley Hospital-Hazleton
-
Investigatore principale:
- Maged Khalil, MD
-
Contatto:
- Numero di telefono: 7347127251
- Email: MCRCwebsitecontactform@trinity-health.org
-
Philadelphia, Pennsylvania, Stati Uniti, 19111
- Reclutamento
- Fox Chase Cancer Center
-
Investigatore principale:
- Margaret von Mehren, MD
-
Contatto:
- Fathima S Sheriff
- Numero di telefono: 215-728-4094
- Email: fathima.sheriff@fccc.edu
-
-
South Carolina
-
Bluffton, South Carolina, Stati Uniti, 29910
- Reclutamento
- SC Cancer Specialists at St. Joseph's/Candler Bluffton
-
Investigatore principale:
- Mark Taylor, MD
-
Contatto:
- Stephanie Smith, RN, MSN, OCN
- Numero di telefono: 19128195723
- Email: smiths1@sjchs.org
-
Bluffton, South Carolina, Stati Uniti, 29910
- Reclutamento
- St. Joseph's/Candler Smith
-
Investigatore principale:
- Mark Taylor, MD
-
Contatto:
- Stephanie Smith, RN, MSN, OCN
- Numero di telefono: 19128195723
- Email: smiths1@sjchs.org
-
Bluffton, South Carolina, Stati Uniti, 29910
- Reclutamento
- Summit Cancer Care at St. Josph's/Candler Bluffton
-
Investigatore principale:
- Mark Taylor, MD
-
Contatto:
- Stephanie Smith, RN, MSN, OCN
- Numero di telefono: 19128195723
- Email: smiths1@sjchs.org
-
Hilton Head Island, South Carolina, Stati Uniti, 29926
- Reclutamento
- South Carolina Cancer Specialists
-
Investigatore principale:
- Mark Taylor, MD
-
Contatto:
- Stephanie Smith, RN, MSN, OCN
- Numero di telefono: 19128195723
- Email: smiths1@sjchs.org
-
-
South Dakota
-
Sioux Falls, South Dakota, Stati Uniti, 57104
- Reclutamento
- Sanford Cancer Center Oncology Clinic and Pharmacy
-
Investigatore principale:
- Steven Powell, MD
-
Contatto:
- Steven Powell, MD
- Numero di telefono: 605-328-8000
- Email: steven.powell@sanfordhealth.org
-
-
Tennessee
-
Nashville, Tennessee, Stati Uniti, 37203
- Reclutamento
- Tennessee Oncology - Nashville / Sarah Cannon Research Institute
-
Contatto:
- Ethan Trull
- Numero di telefono: 615-329-7274
- Email: Ethan.Trull@SarahCannon.com
-
Investigatore principale:
- Meredith McKean, MD, MPH
-
-
Texas
-
Houston, Texas, Stati Uniti, 77030
- Reclutamento
- The University of Texas MD Anderson Cancer Center
-
Investigatore principale:
- Funda Meric-Bernstam, MD
-
Contatto:
- Kshipra Sharma, MPH, MS
- Numero di telefono: 713-745-8431
- Email: Ksharma2@MDAnderson.org
-
-
Utah
-
Cedar City, Utah, Stati Uniti, 84720
- Reclutamento
- Cedar City Hospital, SW Cancer Clinic, Sandra Maxwell Cancer Center
-
Investigatore principale:
- Ramya Thota, MD
-
Contatto:
- Jake Kolu
- Numero di telefono: 435-705-1632
- Email: Jake.Kolu@imail.org
-
Investigatore principale:
- Derrick Haslem, MD
-
Salt Lake City, Utah, Stati Uniti, 84107
- Reclutamento
- Intermountain Healthcare
-
Contatto:
- Tracy Taylor
- Numero di telefono: 801-507-3953
- Email: tracy.taylor@imail.org
-
Investigatore principale:
- Ramya Thota, M.D.
-
Investigatore principale:
- Derrick Haslem, M.D.
-
St. George, Utah, Stati Uniti, 84770
- Reclutamento
- Dixie Regional Medical Center-River Road Campus
-
Investigatore principale:
- Ramya Thota, MD
-
Contatto:
- Jake Kolu
- Numero di telefono: 435-705-1632
- Email: Jake.Kolu@imail.org
-
Investigatore principale:
- Derrick Haslem, MD
-
-
Virginia
-
Fairfax, Virginia, Stati Uniti, 22042
- Reclutamento
- Inova Schar Cancer Institute
-
Investigatore principale:
- Timothy Cannon, MD
-
Contatto:
- Roxana Comfort, CRC
- Numero di telefono: 571-472-0628
- Email: roxana.comfort@inova.org
-
-
Washington
-
Bonney Lake, Washington, Stati Uniti, 98391
- Reclutamento
- Northwest Medical Specialties
-
Contatto:
- Jennifer Spokely
- Numero di telefono: 253-999-3701
- Email: research@southsoundcare.org
-
Investigatore principale:
- Frank Senecal, MD
-
Federal Way, Washington, Stati Uniti, 98003
- Reclutamento
- Northwest Medical Specialties
-
Contatto:
- Jennifer Spokely
- Numero di telefono: 253-999-3701
- Email: research@southsoundcare.org
-
Investigatore principale:
- Frank Senecal, MD
-
Gig Harbor, Washington, Stati Uniti, 98332
- Reclutamento
- Northwest Medical Specialties
-
Contatto:
- Jennifer Spokely
- Numero di telefono: 253-999-3701
- Email: research@southsoundcare.org
-
Investigatore principale:
- Frank Senecal, MD
-
Olympia, Washington, Stati Uniti, 98502
- Reclutamento
- Northwest Medical Specialties
-
Contatto:
- Jennifer Spokely
- Numero di telefono: 253-999-3701
- Email: research@southsoundcare.org
-
Investigatore principale:
- Frank Senecal, MD
-
Puyallup, Washington, Stati Uniti, 98373
- Reclutamento
- Northwest Medical Specialties
-
Investigatore principale:
- Frank Senecal, MD
-
Contatto:
- Jennifer Spokely
- Numero di telefono: 253-999-3701
- Email: reserch@southsoundcare.org
-
Seattle, Washington, Stati Uniti, 98104
- Reclutamento
- Swedish Cancer Institute
-
Investigatore principale:
- Philip Gold, MD
-
Contatto:
- Sidney Ching
- Numero di telefono: 206-386-3142
- Email: sidney.ching@swedish.org
-
Tacoma, Washington, Stati Uniti, 98405
- Reclutamento
- Northwest Medical Specialties
-
Investigatore principale:
- Frank Senecal, MD
-
Contatto:
- Jennifer Spokely
- Numero di telefono: 253-999-3701
- Email: reserch@southsoundcare.org
-
-
Wisconsin
-
Burlington, Wisconsin, Stati Uniti, 53105
- Reclutamento
- Aurora Cancer Care - Burlington
-
Investigatore principale:
- Antony Ruggeri, MD
-
Contatto:
- Michelle Toutloff, RN, CCRP
- Numero di telefono: 9204567880
- Email: Michelle.Martin2@aah.org
-
Germantown, Wisconsin, Stati Uniti, 53022
- Reclutamento
- Aurora Health Care - Germantown Health Center
-
Investigatore principale:
- Antony Ruggeri, MD
-
Contatto:
- Michelle Toutloff, RN, CCRP
- Numero di telefono: 9204567880
- Email: Michelle.Martin2@aah.org
-
Grafton, Wisconsin, Stati Uniti, 53024
- Reclutamento
- Aurora Cancer Care - Grafton
-
Investigatore principale:
- Antony Ruggeri, MD
-
Contatto:
- Michelle Toutloff, RN, CCRP
- Numero di telefono: 9204567880
- Email: Michelle.Martin2@aah.org
-
Green Bay, Wisconsin, Stati Uniti, 54311
- Reclutamento
- Aurora BayCare Medical Center
-
Investigatore principale:
- Antony Ruggeri, MD
-
Contatto:
- Michelle Toutloff, RN, CCRP
- Numero di telefono: 9204567880
- Email: Michelle.Martin2@aah.org
-
Kenosha, Wisconsin, Stati Uniti, 53142
- Reclutamento
- Aurora Cancer Care - Kenosha South
-
Investigatore principale:
- Antony Ruggeri, MD
-
Contatto:
- Michelle Toutloff, RN, CCRP
- Numero di telefono: 9204567880
- Email: Michelle.Martin2@aah.org
-
Marinette, Wisconsin, Stati Uniti, 54143
- Reclutamento
- Aurora Bay Area Medical Center
-
Investigatore principale:
- Antony Ruggeri, MD
-
Contatto:
- Michelle Toutloff, RN, CCRP
- Numero di telefono: 9204567880
- Email: Michelle.Martin2@aah.org
-
Milwaukee, Wisconsin, Stati Uniti, 53215
- Reclutamento
- Aurora St. Luke's Medical Center
-
Investigatore principale:
- Antony Ruggeri, MD
-
Contatto:
- Michelle M Toutloff, RN, CCRP
- Numero di telefono: 9204567880
- Email: Michelle.Martin2@aah.org
-
Milwaukee, Wisconsin, Stati Uniti, 53209
- Reclutamento
- Aurora Cancer Care Milwaukee
-
Investigatore principale:
- Antony Ruggeri, MD
-
Contatto:
- Michelle M Toutloff, RN, CCRP
- Numero di telefono: 9204567880
- Email: Michelle.Martin2@aah.org
-
Milwaukee, Wisconsin, Stati Uniti, 53223
- Reclutamento
- Aurora Sinai Medical Center
-
Investigatore principale:
- Antony Ruggeri, MD
-
Contatto:
- Michelle Toutloff, RN, CCRP
- Numero di telefono: 9204567880
- Email: Michelle.Martin2@aah.org
-
Milwaukee, Wisconsin, Stati Uniti, 53227
- Reclutamento
- Aurora West Allis Medical Center
-
Investigatore principale:
- Antony Ruggeri, MD
-
Contatto:
- Michelle Toutloff, RN, CCRP
- Numero di telefono: 9204567880
- Email: Michelle.Martin2@aah.org
-
Oshkosh, Wisconsin, Stati Uniti, 54904
- Reclutamento
- Vince Lombardi Cancer Clinic - Oshkosh
-
Investigatore principale:
- Antony Ruggeri, MD
-
Contatto:
- Michelle Toutloff, RN, CCRP
- Numero di telefono: 9204567880
- Email: Michelle.Martin2@aah.org
-
Racine, Wisconsin, Stati Uniti, 53406
- Reclutamento
- Aurora Cancer Care - Racine
-
Investigatore principale:
- Antony Ruggeri, MD
-
Contatto:
- Michelle Toutloff, RN, CCRP
- Numero di telefono: 9204567880
- Email: Michelle.Martin2@aah.org
-
Sheboygan, Wisconsin, Stati Uniti, 53081
- Reclutamento
- Vince Lombardi Cancer Center
-
Investigatore principale:
- Antony Ruggeri, MD
-
Contatto:
- Michelle Toutloff, RN, CCRP
- Numero di telefono: 9204567880
- Email: Michelle.Martin2@aah.org
-
Summit, Wisconsin, Stati Uniti, 53066
- Reclutamento
- Aurora Medical Center in Summit
-
Investigatore principale:
- Antony Ruggeri, MD
-
Contatto:
- Michelle Toutloff, RN, CCRP
- Numero di telefono: 9204567880
- Email: Michelle.Martin2@aah.org
-
Two Rivers, Wisconsin, Stati Uniti, 54241
- Reclutamento
- Vince Lombardi Cancer Clinic - Two Rivers
-
Investigatore principale:
- Antony Ruggeri, MD
-
Contatto:
- Michelle Toutloff, RN, CCRP
- Numero di telefono: 9204567880
- Email: Michelle.Martin2@aah.org
-
Wauwatosa, Wisconsin, Stati Uniti, 53226
- Reclutamento
- Aurora Cancer Care - Milwaukee West
-
Investigatore principale:
- Antony Ruggeri, MD
-
Contatto:
- Michelle Toutloff, RN, CCRP
- Numero di telefono: 920-456-7880
- Email: Michelle.Martin2@aah.org
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
12 years of age or older (*Restrictions apply. Not all therapies are available for patients <18)
-
Histologically-proven locally advanced or metastatic solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma who is no longer benefiting from standard anti-cancer treatment or for whom, in the opinion of the treating physician, no such treatment is available or indicated (except under the circumstance in which the TAPUR arm is designed to provide additional evidence to support an existing FDA indication).
-
Performance status 0-2 (Per Eastern Cooperative Oncology Group (ECOG) criteria)
-
Patients must have acceptable organ function as defined below. However, as noted above, drug-specific inclusion/exclusion criteria specified in the protocol appendix for each agent will take precedence for this and all inclusion criteria:
- Absolute neutrophil count ≥ 1500 µl
- Hemoglobin ≥ 9.0 g/dl
- Platelets ≥ 75,000/µl
- Total bilirubin < 2.0 mg/ dl, except in patients with Gilbert's Syndrome
- Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT) < 2.5 x institutional upper limit of normal (ULN) (or < 5 x ULN in patients with known hepatic metastases)
- Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 50 mL/min/1.73 m2
-
Patients must have disease that can be objectively measured by physical, laboratory or radiographic exam (per RECIST v1.1 for solid tumor, Lugano criteria for non-Hodgkin lymphoma or International Myeloma Working Group criteria for multiple myeloma).
-
Results must be available from a genomic test or immunohistochemistry (IHC) test for protein expression performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited or New York State accredited (for labs offering services to residents of NY) laboratory. Labs that have registered the test with the NIH Genetic Testing Registry or that provide a report that has been designated as optimized for TAPUR participation are preferred, but not required. The genomic or IHC test used to qualify a patient for participation in TAPUR may have been performed on any specimen of the patient's tumor obtained at any point during the patient's care at the discretion of the patient's treating physician. Genomic assays performed on cell-free DNA in plasma ("liquid biopsies") will also be acceptable if the genomic analysis is performed in a laboratory that meets the criteria described above.
-
Ability to understand and the willingness to sign a written informed consent/assent document.
-
Have a tumor genomic profile for which single agent treatment with one of the FDA approved targeted anti-cancer drugs included in this study has potential clinical benefit based on the criteria described in protocol.
-
For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome.
-
Because of the risks of drug treatment to the developing fetus, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for four months following completion of study therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study or if she is the partner of a male participant in this study and becomes pregnant while he is participating in this study, she should inform her or her partner's treating physician immediately as well as her obstetrician. Female study patients who become pregnant must immediately discontinue treatment with any study therapy. Male patients should avoid impregnating a female partner. Male study patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and for a specified amount of time the last dose of study treatment, or completely abstain from sexual intercourse.
Note: TAPUR does not explicitly exclude any type of solid tumor, but the patient must have measurable and evaluable disease per RECIST v1.1.
Exclusion Criteria:
- Patients whose disease is not measurable or cannot be assessed by radiographic imaging or physical examination (e.g., elevated serum tumor marker only) are not eligible
- Patients with primary brain tumors or new, untreated or progressive leptomeningeal metastases are excluded
- Patients with previously treated brain metastases or previously treated leptomeningeal disease are eligible, provided that the patient has not experienced a seizure or had a clinically significant change in neurological status within the 1 months prior to registration. All patients with previously treated brain metastases must be clinically stable for at least 1 month after completion of treatment and off steroid treatment for one month prior to study enrollment.
- Patients with known progressive brain metastases are eligible but additional eligibility criteria apply.
Note: there are additional exclusion criteria that may apply
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Altro: Group 5 (CSF1R,PDGFR,VEGFR)
Participants receive sunitinib - dosage, frequency and duration per label; acceptable genomic matches include CSF1R, PDGFR, VEGFR1/2/3, KIT, FLT-3, RET, FGFR1/2/3, VHL amplifications or mutations |
drug
Altri nomi:
|
|
Altro: Group 8 (ERBB2)
Participants receive trastuzumab and pertuzumab - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression, and specific ERBB2 mutations |
drug
Altri nomi:
|
|
Altro: Group 9 (BRAF V600E/D/K/R)
Participants receive vemurafenib and cobimetinib - dosage, frequency and duration per label; acceptable genomic matches include BRAF V600E/D/K/R mutations |
drug
Altri nomi:
|
|
Altro: Group 14 (BRCA1/2; ATM)
Participants receive olaparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 inactivating mutations; ATM mutations or deletions |
drug
Altri nomi:
|
|
Altro: Group 16 (MSI-H, high mutational load and others)
Participants receive nivolumab and ipilimumab - dosage, frequency and duration per label; acceptable genomic matches include MSI high status, high tumor mutational burden, MLH1, MSH2/6, PMS2, EPCAM mutations, specific POLE or POLD1 mutations, BRCA1/2, ATM, MSH3, PMS1, MLH3, EXO1, RFC1/2/3/4/5, PCNA, RPA1/2/3/4, and SSBP1 loss of function mutations |
drug
Altri nomi:
|
|
Altro: Group 17 (CDKN2A, CDK4, CDK6)
Participants receive abemaciclib - dosage, frequency and duration per label; acceptable genomic matches include CDKN2A loss or mutation, CDK4, CDK6 amplifications, CDKN2B loss or mutation |
drug
Altri nomi:
|
|
Altro: Group 19 (BRCA1/2, PALB2)
Participants receive talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 and PALB2 mutations |
drug
Altri nomi:
|
|
Altro: Group 21 (BRCA1/2, PALB2, ATM, and others)
Participants receive atezolizumab plus talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic mutations in BRCA1/2, PALB2, ATM, ATR, CHEK2, FANCA, RAD51C, NBN, MLH1, MRE11A, CDK12; positive genomic instability score reported on the Myriad MyChoice CDx test; or Genomic Loss of Heterozygosity (LOH) Score above threshold as reported on a FoundationOne CDx test or another qualifying test for TAPUR with MTB approval |
drug
Altri nomi:
|
|
Altro: Group 24 (ERBB2)
Participants receive tucatinib plus trastuzumab SC - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression, and specific ERBB2 mutations |
drug
Altri nomi:
|
|
Altro: Group 25
Participants receive futibatinib- dosage, frequency and duration per label; acceptable genomic matches include FGFR 1,2,3,4 fusion (or other rearrangement) or mutation |
drug
Altri nomi:
|
|
Altro: Group 26 (BRAF V600 E mutation )
Participants receive Dabrafenib plus Trametinib - dosage, frequency and duration per label; acceptable genomic matches include BRAF V600 E mutation . |
Drug
Altri nomi:
|
|
Altro: Group 27 (ERBB2 amplification, ERBB2 (HER2) IHC2+ or IHC3+ overexpression)
Participants receive Fam-trastuzumab deruxtecan-nxki (ENHERTU®) - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification, For NSCLC Only-ERBB2 (HER2) IHC2+ or IHC3+ overexpression without ERBB2 amplification) |
Drug
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Objective Response Rate defined as % of participants in a cohort with complete or partial response or with stable disease according to standard response criteria
Lasso di tempo: Assessed at 16 weeks of treatment
|
Each cohort includes participants with the same tumor type, genomic variant and study drug. For solid tumors, the Response Evaluation Criteria for Solid Tumors (RECIST) criteria will be used, for non-Hodgkin Lymphoma, the Lugano Criteria will be used, and for multiple myeloma, the International Uniform Response Criteria for Multiple Myeloma will be used. |
Assessed at 16 weeks of treatment
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Overall survival (OS)
Lasso di tempo: Duration of survival from registration on study until death from any cause, assessed throughout end of study, up to 3 years
|
OS will be estimated using the Kaplan-Meier method |
Duration of survival from registration on study until death from any cause, assessed throughout end of study, up to 3 years
|
Collaboratori e investigatori
Pubblicazioni e link utili
Pubblicazioni generali
- Alva AS, Mangat PK, Garrett-Mayer E, Halabi S, Hansra D, Calfa CJ, Khalil MF, Ahn ER, Cannon TL, Crilley P, Fisher JG, Haslem DS, Shrestha S, Antonelli KR, Butler NL, Warren SL, Rygiel AL, Ranasinghe S, Bruinooge SS, Schilsky RL. Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. J Clin Oncol. 2021 Aug 1;39(22):2443-2451. doi: 10.1200/JCO.20.02923. Epub 2021 Apr 12.
- Fisher JG, Tait D, Garrett-Mayer E, Halabi S, Mangat PK, Schink JC, Alvarez RH, Veljovich D, Cannon TL, Crilley PA, Pollock T, Calfa CJ, Al Baghdadi T, Thota R, Fleming N, Cotta JA, Rygiel AL, Warren SL, Schilsky RL. Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Target Oncol. 2020 Dec;15(6):733-741. doi: 10.1007/s11523-020-00753-7.
- Al Baghdadi T, Garrett-Mayer E, Halabi S, Mangat PK, Rich P, Ahn ER, Chai S, Rygiel AL, Osayameh O, Antonelli KR, Islam S, Bruinooge SS, Schilsky RL. Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Target Oncol. 2020 Dec;15(6):743-750. doi: 10.1007/s11523-020-00752-8.
- Gupta R, Meric-Bernstam F, Rothe M, Garrett-Mayer E, Mangat PK, D'Andre S, Ahn ER, O'Lone R, Halabi S, Grantham GN, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study. JCO Precis Oncol. 2022 Oct;6:e2200306. doi: 10.1200/PO.22.00306.
- Mangat PK, Kirkwood MK, Hinshaw DC, Garrett-Mayer E, Schilsky RL. Prevalence of targetable genomic alterations among a diverse population participating in the ASCO TAPUR Study. NPJ Precis Oncol. 2025 Jul 3;9(1):222. doi: 10.1038/s41698-025-00962-1.
- Worden FP, Pisick E, Rothe M, Mangat PK, Garrett-Mayer E, Khalil MF, Carrizosa DR, Bauman JR, Leidner RS, Duvivier HL, Fu S, Park MS, Yost KJ, Calfa CJ, Marr AS, Balmanoukian AS, Behl D, Cannon TL, Nabell L, Powell SF, Thota R, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Oct;8:e2400477. doi: 10.1200/PO-24-00477. Epub 2024 Oct 16.
- Schuetze S, Rothe M, Mangat PK, Garrett-Mayer E, Meric-Bernstam F, Calfa CJ, Farrington LC, Livingston MB, Wentzel K, Behl D, Kier Y, Marr AS, von Mehren M, Press JZ, Thota R, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL. Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Jul;8:e2400219. doi: 10.1200/PO.24.00219.
- Srkalovic G, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Brouse G, Chan J, Mehmi I, Khalil M, Duvivier HL, Gaba A, Leuva H, Thota R, Yost KJ, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL. Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Jun;8:e2400026. doi: 10.1200/PO.24.00026.
- Cannon TL, Rothe M, Mangat PK, Garrett-Mayer E, Chiu VK, Hwang J, Vijayvergia N, Alese OB, Dib EG, Duvivier HL, Klute KA, Sahai V, Ahn ER, Bedano P, Behl D, Sinclair S, Thota R, Urba WJ, Yang ES, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. J Clin Oncol. 2024 Sep 20;42(27):3228-3237. doi: 10.1200/JCO.23.02078. Epub 2024 May 15.
- Perez JK, Kleber J, Rothe M, Mangat P, Garrett-Mayer E, Schilsky RL. Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study. JCO Precis Oncol. 2024 Mar;8:e2300615. doi: 10.1200/PO.23.00615.
- Calfa CJ, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Burness ML, Gogineni K, Rohatgi N, Al Baghdadi T, Conlin A, Gaba A, Hamid O, Krishnamurthy J, Gavini NJ, Gold PJ, Rodon J, Rueter J, Thota R, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Feb;8:e2300513. doi: 10.1200/PO.23.00513.
- Meric-Bernstam F, Rothe M, Mangat PK, Garrett-Mayer E, Gutierrez R, Ahn ER, Cannon TL, Powell S, Krauss JC, Reynolds CM, von Mehren M, Behl D, Calfa CJ, Duvivier HL, Kaplan HG, Livingston MB, Sharma MR, Urba WJ, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2023 Sep;7:e2300385. doi: 10.1200/PO.23.00385.
- Rohatgi N, Rothe M, Mangat PK, Garrett-Mayer E, Meric-Bernstam F, Pisick E, Alese OB, Reynolds CM, Thota R, Vaccaro GM, von Mehren M, Arend RC, Chiu VK, Duvivier HL, Gold PJ, Hack K, Marr AS, Winer A, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2023 Sep;7:e2300279. doi: 10.1200/PO.23.00279.
- Duvivier HL, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Al Baghdadi T, Alva AS, Dublis SA, Cannon TL, Calfa CJ, Li R, Behl D, Chiu VK, Gold PJ, Marr AS, Mileham KF, Powell SF, Rodon J, Thota R, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL. Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study. J Clin Oncol. 2023 Nov 20;41(33):5140-5150. doi: 10.1200/JCO.23.00702. Epub 2023 Aug 10.
- Mangat PK, Garrett-Mayer E, Perez JK, Schilsky RL. The Targeted Agent and Profiling Utilization Registry Study: A pragmatic clinical trial. Clin Trials. 2023 Dec;20(6):699-707. doi: 10.1177/17407745231182013. Epub 2023 Jul 25.
- Ganti AK, Rothe M, Mangat PK, Garrett-Mayer E, Dib EG, Duvivier HL, Ahn ER, Behl D, Borghaei H, Balmanoukian AS, Gaba A, Li R, Osei-Boateng K, Thota R, Grantham GN, Gregory A, Halabi S, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2023 Jun;7:e2300041. doi: 10.1200/PO.23.00041.
- Ahn ER, Rothe M, Mangat PK, Garrett-Mayer E, Ali-Ahmad HM, Chan J, Maitland ML, Patel SR, Reese Z, Balmanoukian AS, Drescher CW, Li R, Tsimberidou AM, Leath CA 3rd, O'Lone R, Grantham GN, Halabi S, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study. JCO Precis Oncol. 2023 Apr;7:e2200609. doi: 10.1200/PO.22.00609.
- Yang ES, Halabi S, Rothe M, Garrett-Mayer E, Mangat PK, Pisick E, Dib E, Burgess EF, Zakem M, Rohatgi N, Bilen MA, O'Lone R, Grantham GN, Schilsky RL. Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study. JCO Precis Oncol. 2023 Feb;7:e2200505. doi: 10.1200/PO.22.00505.
- Carrizosa DR, Rothe M, Mangat PK, Garrett-Mayer E, Behl D, Adesunloye B, Pisick E, Beekman KW, Dotan E, Akce M, Alese OB, Sahai V, Klute KA, Aragon-Ching JB, Cooper KA, Thota R, Meric-Bernstam F, Hosein PJ, Maestas EC, Moyers JT, Powell S, Zhao S, Hobbs E, Rueter J, Sohal DPS, Taylor MA, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2026 Jan;10:e2500716. doi: 10.1200/PO-25-00716. Epub 2026 Jan 15.
- Al Baghdadi T, Rothe M, Mangat PK, Garrett-Mayer E, Crysler OV, Mileham KF, Farrington LC, Adesunloye B, Dublis SA, Astsaturov I, Calfa CJ, Bleeker J, Khalil M, Thota R, Cannon TL, Alese OB, Gold PJ, Hafez N, Baron AD, Meric-Bernstam F, Hobbs E, Marr AS, Rueter J, Tawfik B, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2025 Oct;9:e2500649. doi: 10.1200/PO-25-00649. Epub 2025 Oct 16.
- Cobain EF, Rothe M, Garrett-Mayer E, Cannon TL, Chan JK, Mileham KF, Adesunloye B, Calfa CJ, Alese OB, Butler KY, Dib EG, Pisick E, Bell M, Klute KA, Mehmi I, Meric-Bernstam F, Mangat PK, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2026 Apr;10(4):e2501205. doi: 10.1200/PO-25-01205. Epub 2026 Apr 30.
- Pisick E, Rothe M, Garrett-Mayer E, Srkalovic G, Chan JK, Calfa CJ, Leath CA 3rd, Marr AS, Gold PJ, Crane EK, Moyers JT, Yost Butler K, Gaba A, Thota R, Harnden KK, Alese OB, Jain A, Rueter J, Gill S, George TJ, Frimer M, Kayali F, Mangat PK, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Temsirolimus in Patients With Solid Tumors With PIK3CA Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2026 Apr;10(4):e2500985. doi: 10.1200/PO-25-00985. Epub 2026 Apr 22.
- Veljovich DS, Rothe M, Garrett-Mayer E, Ali-Ahmad HM, Naumann RW, Siedel J, Chan JK, Gregory A, Pisick E, Adesunloye B, Arend RC, Bell M, Frimer M, Tawfik B, Thota R, Tsimberidou AM, Mangat PK, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Palbociclib in Patients With Ovarian Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2026 Jul;10(7):e2600456. doi: 10.1200/PO-26-00456. Epub 2026 Jul 15.
- Diamond-Rossi SA, Rothe M, Garrett-Mayer E, Pisick E, Bleeker J, Ganti AK, Meric-Bernstam F, Moyers JT, Nair SG, Kadakia KC, Rohatgi N, Sahai V, Vijayvergia N, Gold PJ, Sharma MR, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Cobimetinib + Vemurafenib in Patients With BRAF V600E-Mutant Papillary Thyroid and Biliary Tract Cancers: Results From the TAPUR Study. JCO Precis Oncol. 2026 Oct;10(10):e2600703. doi: 10.1200/PO-26-00703. Epub 2026 Oct 16.
- Srkalovic G, Rothe M, Garrett-Mayer E, Mileham KF, Adesunloye B, Pisick E, Leath CA 3rd, Colocci N, Chen MD, Meric-Bernstam F, Marr AS, Alese OB, Powell S, Rueter J, Benyounes A, Pontious C, Lewis MA, Thomas GW, Kier Y, Calfa CJ, von Mehren M, Acoba JD, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Sunitinib in Patients With Various Solid Tumors With FGFR1/2 Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2026 Oct;10(10):e2600454. doi: 10.1200/PO-26-00454. Epub 2026 Oct 7.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stimato)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie vascolari
- Malattia cardiovascolare
- Malattie del sistema immunitario
- Neoplasie per tipo istologico
- Malattie ematologiche
- Malattie linfatiche
- Malattie linfoproliferative
- Disturbi immunoproliferativi
- Linfoma
- Neoplasie, plasmacellule
- Disturbi emostatici
- Paraproteinemie
- Disturbi delle proteine del sangue
- Disturbi emorragici
- Malattie emiche e linfatiche
- Neoplasie
- Mieloma multiplo
- Linfoma non Hodgkin
- Aminoacidi, peptidi e proteine
- Proteine
- Composti di zolfo
- Prodotti chimici organici
- Composti eterociclici, 1-anello
- Composti eterociclici
- Composti eterociclici, 2 anelli
- Composti eterociclici, anello fuso
- Azoli
- Amides
- Indoli
- Anticorpi, monoclonali, umanizzati
- Anticorpi, monoclonali
- Anticorpi
- Immunoglobuline
- Immunoproteine
- Proteine del sangue
- Globuline sieriche
- Globuline
- Pirroli
- Sulfonamidi
- Solfoni
- Trastuzumab
- Sunitinib
- Nivolumab
- Ipilimumab
- Vemurafenib
- Abemaciclib
- pertuzumab
- Dabrafenib
- trametinib
- atezolizumab
- olaparib
- Talazoparib
- cobimetinib
- Tucatinib
- FUSTIBATinib
Altri numeri di identificazione dello studio
- Pro00014171
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .